UK Life Science Marketbeat Report

For the data behind the commentary, download the full Q1 2026 UK Life Sciences Report

UK Life Science Grants and Investment Commitments Boost UK Prospects 

The Life Sciences Innovative Manufacturing Fund (LSIMF) is a UK government capital grant programme designed to scale domestic manufacturing capacity for medicines, diagnostics and MedTech, introduced to strengthen the UK’s supply chain resilience, attract global investment, and support the commercialisation of innovation. The initial concept was announced in March 2022, before being expanded into a £520m fund in October 2024. The programme was subsequently reaffirmed as one of the government’s six headline actions within the Life Sciences Sector Plan published in July 2025, reinforcing the central role of manufacturing in the UK’s long-term life sciences growth strategy. 

So far, the LSIMF has supported three recent pharma manufacturing investments totalling over £80 million. These include Accord’s expansion in Barnstaple, a new near-patient biomanufacturing facility in Birmingham led by the Precision Health Technologies Accelerator, and Codis’ development of a spray-drying facility in Haverhill. Notably, none of these investments are located within the core Golden Triangle. Whilst these investments are concentrated outside the core of the Golden Triangle, they reflect the growing prospect of the UK’s life sciences ecosystem more widely. 

More recently, AstraZeneca announced a major new investment in Cambridge, advancing plans for a state-of-the-art R&D and manufacturing facility within the Cambridge Biomedical Campus. The scheme reinforces Cambridge’s position as a leading global life sciences cluster and highlights the Golden Triangle’s ability to attract large-scale, globally mobile capital, supporting occupier demand and underpinning long-term growth across its lab and office markets. 

When we reflected on the Life Sciences Sector Plan after its release last year, we noted that it signalled a welcome shift towards delivery and accountability, but acknowledged that real progress would depend on addressing structural challenges across clinical trials, pricing, and university spinouts, alongside unlocking demand to fully utilise an increasingly well-supplied lab development pipeline. 

While the LSIMF represents a positive step in unlocking this demand, progress across these broader structural challenges will be critical to fully realising the sector’s growth potential.  

Disclaimer: The views expressed in this report are provided for general informational purposes only and do not constitute investment advice or a solicitation.